Market Expansion The company's launch of FDA-approved nasal spray Tyrvaya and its placement on major formularies such as Express Scripts indicates strong adoption within the ophthalmic and dry eye treatment markets, suggesting potential for expanding distribution channels and increasing market penetration.

Strategic Acquisition Viatris acquisition of Oyster Point Pharma for approximately 415 million USD presents an opportunity to coordinate with a larger pharmaceutical entity, potentially facilitating broader access to healthcare providers and healthcare systems.

Innovation Focus Oyster Point’s focus on first-in-class therapies for ophthalmic diseases, combined with recent product approvals and its small but specialized team, creates opportunities for targeted outreach to ophthalmologists and eye care clinics eager to adopt innovative treatments.

Financial Stability With revenues between 25 and 50 million USD and substantial funding of 223 million USD, the company shows solid financial backing, creating opportunities for strategic partnerships, co-marketing, or joint ventures to accelerate market expansion.

Technology and Data Utilization of diverse tech platforms like IQVIA for data analysis and compliance, alongside cloud tools like Office 365, suggests an openness to digital solutions and analytics services that can enhance sales targeting, customer engagement, and market research efforts.